Molekulare Grundlagen des Prostatakarzinoms

  • Ursula Elsässer-Beile
  • Wolfgang Schultze-Seemann
  • Ulrich Wetterauer
Part of the Molekulare Medizin book series (MOLMED)


Das Prostatakarzinom (PCa) ist heute weltweit das häufigste Karzinom des Mannes und die zweithäufigste Krebstodesursache (Parker et al. 1996). Pro Jahr werden in der Bundesrepublik etwa 10000 Todesfälle registriert, womit das PCa hinsichtlich der Sterblichkeit knapp hinter dem Bronchialkarzinom steht. Es ist heute davon auszugehen, dass jeder 11. Mann an einem PCa erkrankt und jeder 30. daran sterben wird.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM (1999) Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 39:8–15PubMedGoogle Scholar
  2. Abdulkadir SA, Carvalhal GF, Kaleem Z et al. (2000) Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 31:443–447PubMedGoogle Scholar
  3. Akimoto S, Okumura A, Fuse H (1998) Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.Endocr J 45:183–189PubMedGoogle Scholar
  4. Ali M, Lemoine NR, Ring CJ (1994) The use of DNA viruses as vectors for gene therapy. Gene Ther 1:367–384PubMedGoogle Scholar
  5. Angelsen A, Sandvik AK, Syversen U, Stridsberg M, Waldum H.L. (1998) NGF-beta, NE-cells and prostatic cancer cell lines. A study of neuroendocrine expression in the human prostatic cancer cell lines DU-14S, PC-3, LNCaP, and TSU-pr1 following stimulation of the nerve growth factor-beta. Scand J Urol Nephrol 32:7–13PubMedGoogle Scholar
  6. Apakama I, Robinson MC, Walter NM et al. (1996) bcl-2 overexpression combined with pS3 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 74:1258–1262PubMedCentralPubMedGoogle Scholar
  7. Aro J (1991) Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate 18:131PubMedGoogle Scholar
  8. Arrowsmith CH, Morin P (1996) New insights into p53 function from structural studies. Oncogene 12:1379–1385PubMedGoogle Scholar
  9. Autzen P, Robson CN, Bjartell A et al. (1998) Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78:1219–1223PubMedCentralPubMedGoogle Scholar
  10. Bangma CH, Kranse R, Blijenberg BG et al. (1995) The value of screening tests in the detection of prostate cancer: part I–results of a retrospective evaluation of 1726 men.Urology 46:773–778PubMedGoogle Scholar
  11. Barnes J, Anthony CT, Wall N, Steiner MS (1995) Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 13:337–343PubMedGoogle Scholar
  12. Barrack ER (1997) TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31:61–70PubMedGoogle Scholar
  13. Bigler SA, Deering RE, Brawer MK (1993) Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24:220–226PubMedGoogle Scholar
  14. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL (1995) Loss of HLA dass I expression in prostate cancer: implications for immunotherapy. Urology 46:681–687PubMedGoogle Scholar
  15. Blagosklonny MV, El-Deiry WS (1996) In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 67:386–392PubMedGoogle Scholar
  16. Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358PubMedGoogle Scholar
  17. Bonkhoff H, Fixemer T, Remberger K (1998) Relation between bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 34:251–258PubMedGoogle Scholar
  18. Bookstein R (1994) Tumor suppressor genes in prostatic oncogenesis. J Cell Biochem Suppl 19:217–223Google Scholar
  19. Borchers H, Meyers FJ, Gumerlock PH, Stewart SL, deVere White RW (1996) NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas. J Urol 155:2080–2084PubMedGoogle Scholar
  20. Borsellino N, Belldegrun A, Bonavida B (1995) Endogenous interleukin 6 is a resistance factor for cis-diaminedichloroplatinum and etoposide-mediated cytotoxicity of human rostate carcinoma cell lines. Cancer Res 55:4633–4639PubMedGoogle Scholar
  21. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D’ Alessandro N (1999) Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and eisplatin-mediated cytotoxicity. Cancer85:134–144PubMedGoogle Scholar
  22. Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C (1996) Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab 81:612–617PubMedGoogle Scholar
  23. Bouras T, Frauman AG (1999) Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. J Pathol 188:382–388PubMedGoogle Scholar
  24. Brawer MK, Beatie J, Wener MH et al. (1993) Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 150:106–109PubMedGoogle Scholar
  25. Bryden AA, Freemont AJ, Clarke NW, George NJ (1999) Paradoxical expression of E-cadherin in prostatic bone metastases. Br J Urol Int 84:1032–1034Google Scholar
  26. Bubendorf L, Sauter G, Moch H et al. (1996) Prognostic significance of bcl-2 in clinically localized prostate cancer.Am J Pathol 148:1557–1565PubMedCentralPubMedGoogle Scholar
  27. Burney TL, Rockove S, Eiseman JL, Jacobs SC, Kyprianou N (1994) Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate25:177–188PubMedGoogle Scholar
  28. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF, Schalken JA (2000) Complex cadherin expression in human prostate cancer cells. Int J Cancer 85:446–450PubMedGoogle Scholar
  29. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA (1987) Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11:327–337PubMedGoogle Scholar
  30. Cairns P, Polascik TJ, Eby Y et al. (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11:210–212PubMedGoogle Scholar
  31. Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM (1999) Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor. Int J Cancer80:868–874PubMedGoogle Scholar
  32. Carter BS, Ewing CM, Ward WS et al. (1990a) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87:8751–8755PubMedCentralPubMedGoogle Scholar
  33. Carter HB, Piantadosi S, Isaacs JT (1990b) Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143:742–746PubMedGoogle Scholar
  34. Catalona HB, Partin AW, Slawin AL et al. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA279:1542–1547PubMedGoogle Scholar
  35. Chamberlain NL, Driver ED, Miesfeld RL (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22:3181–3186PubMedCentralPubMedGoogle Scholar
  36. Chang CS, Kokontis J, Liao ST (1988) Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 85:7211–7215PubMedCentralPubMedGoogle Scholar
  37. Chekmareva MA, Hollowell CM, Smith RC, Davis EM, LeBeau MM, Rinker-Schaeffer CW (1997) Localization of prostate cancer metastasis-suppressor activity on human chromosome 17. Prostate 33:271–280PubMedGoogle Scholar
  38. Chen T, Wang LH, Farrar WL (2000) Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60:2132–2135PubMedGoogle Scholar
  39. Cheng L, Leibovich BC, Bergstralh EJ et al. (1999) p53 alteration in regionallymph node metastases from prostate carcinoma: a marker for progression? Cancer 85:2455–2459PubMedGoogle Scholar
  40. Cher ML, Bova GS, Moore DH et al. (1996) Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091–3102PubMedGoogle Scholar
  41. Chodak GW, Schoenberg HW (1984) Early detection of prostate cancer by routine screening. JAMA 252:3261–3264PubMedGoogle Scholar
  42. Chung LW, Li W, Gleave ME et al. (1992) Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl 99–105Google Scholar
  43. Cohen P, Peehl DM, Lamson G, Rosenfeld RG (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGFbinding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401–407PubMedGoogle Scholar
  44. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG (1994) Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 79:1410–1415PubMedGoogle Scholar
  45. Colombel M, Symmans F, Gil S et al. (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol 143:390–400PubMedCentralPubMedGoogle Scholar
  46. Connolly JM Rose DP (1990) Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 16:209–218PubMedGoogle Scholar
  47. Connolly JM, Rose DP (1994) Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24:167–175PubMedGoogle Scholar
  48. Cooke PS, Young P, Cunha GR (1991) Androgen receptor expression in developing male reproductive organs. Endocrinology 128:2867–2873PubMedGoogle Scholar
  49. Cooner WH, Mosley BR, Rutherford CL et al. (1988) Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 139:758–761PubMedGoogle Scholar
  50. Crawford ED, Eisenberger MA, McLeod DG (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Eng J Med 321:419–424Google Scholar
  51. Cress AE, Rabinovitz I, Zhu W, Nagle RB (1995) The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 14:219–228PubMedGoogle Scholar
  52. Cronauer MV, Hittmair A, Eder IE et al. (1997) Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative dis orders of the prostate. Prostate 31:223–233PubMedGoogle Scholar
  53. Cronauer MV, Nessler-Menardi C, Klocker H et al. (2000) Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 82:39–45PubMedCentralPubMedGoogle Scholar
  54. Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD (1999) The androgen receptor: genetic considerations in the development and treatment of prostate cancer. J Mol Med 77:419–426PubMedGoogle Scholar
  55. Culig Z, Hobisch A, Hittmair A et al. (1997) Synergistie activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatie carcinoma cells. Prostate 32:106–114PubMedGoogle Scholar
  56. Dalal R, Djakiew D (1997) Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate. Mol Cell Endocrinol 134:15–22PubMedGoogle Scholar
  57. Davies P, Eaton CL (1989) Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate. Prostate 14:123–132PubMedGoogle Scholar
  58. Degeorges A, Tatoud R, Fauvel-Lafeve F et al. (1996) Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 68:207–214PubMedGoogle Scholar
  59. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI (1999) E-cadherin expression as a marker of tumor aggressiveness in routinely processed radieal prostatectomy specimens.Urology 53:707–713PubMedGoogle Scholar
  60. De Winter JA, Trapman J, Brinkmann AO et al. (1990) Androgen receptor heterogeneity in human prostatic carcinomas visualized-by immunohistochemistry. J Pathol 160:329–332PubMedGoogle Scholar
  61. Djakiew D (2000) Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42: 150–160PubMedGoogle Scholar
  62. Dong JT, Rinker-Schaeffer CW, Ichikawa T, Barrett JC, Isaacs JT (1996) Prostate cancer-biology of metastasis and its clinical implications. World J Urol 14:182–189PubMedGoogle Scholar
  63. Dorai T, Olsson CA, Katz AE, Buttyan R (1997) Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate 32:246–258PubMedGoogle Scholar
  64. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV (1995) Mutation of the MXI1 gene in prostate cancer. Nat Genet 9:249–255PubMedGoogle Scholar
  65. Eastham JA, Truong LD, Rogers E et al. (1995) Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73:628–635PubMedGoogle Scholar
  66. Eastham JA, Chen SH, Sehgal I et al. (1996) Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciciovir in mouse and human prostate cancer models. Hum Gene Ther 7:515–523PubMedGoogle Scholar
  67. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (1992) Genetic variation at five trimerie and tetrameric tandem repeat loei in four human population groups. Genomics 12:241–253PubMedGoogle Scholar
  68. El-Deiry WS, Harper JW, O’Connor PM et al. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.Cancer Res 54:1169–1174PubMedGoogle Scholar
  69. English HF, Kyprianou N, Isaacs JT (1989) Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration.Prostate 15:233–250PubMedGoogle Scholar
  70. Eskew LA, Bare RL, McCullough DL (1997) Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157:199–203PubMedGoogle Scholar
  71. Felgner PL, Tsai YJ, Sukhu L et al. (1995) Improved cationic lipid formulations for in vivo gene therapy. Ann NY Acad Sci 772: 126-139Google Scholar
  72. Ferrer FA, Miller LJ, Andrawis RI et al. (1997) Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157:2329–2333PubMedGoogle Scholar
  73. Ficazzola MA, Taneja SS (1998) Prospects for gene therapy in human prostate cancer. Mol Med Today 4:494-504Google Scholar
  74. Fornaro M, Manzotti M, Tallini G et al. (1998) Betal C integrin in epithelial cells correlates with a nonproliferative phenotype: forced expression of betal C inhibits prostate epithelial cell proliferation. Am J Pathol 153:1079–1087PubMedCentralPubMedGoogle Scholar
  75. Friedman GD, Hiatt RA, Quesenberry CP et al. (1991) Casecontrol study of screening for prostatic cancer by digital rectal examinations. Lancet 337:1526–1529PubMedGoogle Scholar
  76. Fudge K, Bostwiek DG, Stearns ME (1996) Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatie intraepithelial neoplasia. Prostate 29:282–286PubMedGoogle Scholar
  77. Gaddipati JP, McLeod DG, Heidenberg HB et al. (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861–2864PubMedGoogle Scholar
  78. Gann PH, Hennekens CH, Stampfer MJ (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273:289–294PubMedGoogle Scholar
  79. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ (1993) Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 53:2723–2727PubMedGoogle Scholar
  80. Gao X, Chen YQ, Wu N et al. (1995) Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11:1395–1398PubMedGoogle Scholar
  81. Giri D, Ittmann M (1999) Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30:419–424PubMedGoogle Scholar
  82. Goldenberg SL, Bruchovsky N, Gleave ME et al. (1995) Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45:839–845PubMedGoogle Scholar
  83. Gotoh A, Ko SC, Shirakawa T et al. (1998) Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 160:220–229PubMedGoogle Scholar
  84. Graham CW, Lynch JH, Djakiew D (1992) Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 147:1444–1447PubMedGoogle Scholar
  85. Guo Y, Kyprianou N (1999) Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 59:1366–1371PubMedGoogle Scholar
  86. Hall SJ, Sanford MA, Atkinson G, Chen SH (1998) Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and gancidovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res 58:3221–3225PubMedGoogle Scholar
  87. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN (1997) Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatie tissue. Cancer Res 57:4427–4431PubMedGoogle Scholar
  88. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR (1994) Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24:204–211PubMedGoogle Scholar
  89. Harris DT, Matyas GR, Gomella LG et al. (1999) Immunologic approaches to the treatment of prostate cancer. Semin Oncol 26:439–447PubMedGoogle Scholar
  90. Hassan W, Sanford MA, Woo SL, Chen SH, Hall SJ (2000) Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. World J Urol 18:130–135PubMedGoogle Scholar
  91. Hayward SW, Rosen MA, Cunha GR (1997) Stromal-epithelail interactions in the normal and neoplastic prostate. Br J Urol [Suppl 2] 79:18–26PubMedGoogle Scholar
  92. Herman JG, Merlo A, Mao L et al. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525–4530PubMedGoogle Scholar
  93. Herrmann JL, Beham AW, Sarkiss M et al. (1997) bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res 237:101–109PubMedGoogle Scholar
  94. Ho PJ, Baxter RC (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 46:333–342Google Scholar
  95. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28:129–135PubMedGoogle Scholar
  96. Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334–336PubMedGoogle Scholar
  97. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) BCL2 protein is topographically restrieted in tissues characterized by apoptotie cell death. Proc Natl Acad Sci USA 88:6961–6965PubMedCentralPubMedGoogle Scholar
  98. Hsieh JT, Lin SH (1994) Androgen regulation of cell adhesion molecule gene expression in rat prostate during organ degeneration. C-CAM belongs to a dass of androgen-repressed genes associated with enriehed stem/amplifying cell population after prolonged castration. J Biol Chem 269:3711–3716PubMedGoogle Scholar
  99. Hsieh JT, Luo W, Song W et al. (1995) Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 55:190–197PubMedGoogle Scholar
  100. Hugel A, Wernert N (1999) Loss of heterozygosity (LOH), malignancy grade and donality in microdissected prostate cancer. Br J Cancer 79:551–557PubMedCentralPubMedGoogle Scholar
  101. Huggins C, Bergenstal D (1952) Effect of bilateral adrenalectomy on certain human tumors. Proc Natl Acad Sci USA 38:73–76PubMedCentralPubMedGoogle Scholar
  102. Huggins C, Hodges CV (1941) Studies of prostatic cancer: effects of castration estrogen and androgen injections on serum phosphatases in metastatic carcinoma of prostate.Cancer Res 1:293–307Google Scholar
  103. Huggins C, Scott WW (1945) Bilateral adrenalectomy in prostatic cancer. Clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg 122:1031–1045PubMedCentralGoogle Scholar
  104. Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostatic cancer: H. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223Google Scholar
  105. Humphrey PA, Zhu X, Zarnegar R et al. (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.Am J Pathol 147:386–396PubMedCentralPubMedGoogle Scholar
  106. Ide H, Yoshida T, Matsumoto N et al. (1997) Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57:5022–5027PubMedGoogle Scholar
  107. Igawa M, Urakami S, Shiina H, Ishibe T, Usui T, Chodak GW (1996) Association of nm23 protein levels in human prostates with proliferating cell nuclear antigen expression at autopsy. Eur Urol 30:383–387PubMedGoogle Scholar
  108. Isaacs JT, Kyprianou N (1987) Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urol Res 15:133–138PubMedGoogle Scholar
  109. Isaacs WB, Carter BS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716–4720PubMedGoogle Scholar
  110. Ittman M, Mansukhani A (1997) Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate.J Urol 157:351–356PubMedGoogle Scholar
  111. Izzi L, Turbide C, Houde C, Kunath T, Beauchemin N (1999) cis-Determinants in the cytoplasmic domain of CEA-CAM1 responsible for its tumor inhibitory function. Oncogene 18:5563–5572PubMedGoogle Scholar
  112. Janne OA, Palvimo JJ, Kallio P, Mehto M (1993) Androgen receptor and mechanism of androgen action. Ann Med 25:83–89PubMedGoogle Scholar
  113. Jarrard DF, Kinoshita H, Shi Y et al. (1998) Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58:5310–5314PubMedGoogle Scholar
  114. Jenkins RB, Qian J, Lieber MM, Bostwick DG (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524–531PubMedGoogle Scholar
  115. Jensen SL, Wood DP Jr, Banks ER et al. (1996) Increased levels of nm23H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate. World J Urol 14:S21–S25PubMedGoogle Scholar
  116. Jenster G (1999) The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26:407–421PubMedGoogle Scholar
  117. Jones HE, Eaton CL, Barrow D, Dutkowski CM, Gee JM, Griffiths K (1997) Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 30:219–231PubMedGoogle Scholar
  118. Joseph IB, Isaacs JT (1997) Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 57:1054–1057PubMedGoogle Scholar
  119. Kantoff P, Giovannucci E, Brown M (1998) The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim Biophys Acta 1378:C1–C5PubMedGoogle Scholar
  120. Kawamata N, Park D, Wilczynski S, Yokota J, Koeffler HP (1996) Point mutations of the Mxil gene are rare in prostate cancers. Prostate 29:191–193PubMedGoogle Scholar
  121. Kawana Y, Komiya A, Ueda T et al. (1997) Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 32:205–213PubMedGoogle Scholar
  122. Kemppainen JA, Lane MV, Sar M, Wilson EM (1992) Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267:968–974PubMedGoogle Scholar
  123. Kestin LL, Martinez AA, Stromberg JS et al. (2000) Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 18:2869–2880PubMedGoogle Scholar
  124. Kim IY, Ahn HJ, Zelner DJ et al. (1996) Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2:1255–1261PubMedGoogle Scholar
  125. Kitada S, Takayama S, De RK et al. (1994) Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bel-2 gene expression. Antisense Res Dev 4:71–79PubMedGoogle Scholar
  126. Kleinerman DI, Troncoso P, Lin SH et al. (1995a) Consistent expression of an epithelial cell adhesion molecule (CCAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 55:1215–1220PubMedGoogle Scholar
  127. Kleinerman DI, Zhang WW, Lin SH, Nguyen I.V., Eschenbach AC von, Hsieh JI (1995b) Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res 55:2831–2836PubMedGoogle Scholar
  128. Knudson CM, Korsmeyer SJ (1997) bcl-2 and bax function independently to regulate cell death. Nat Genet 16:358–363PubMedGoogle Scholar
  129. Koeneman KS, Kao C., Ko SC et al. (2000) Osteocalcindirected gene therapy for prostate-cancer bone metasta-sis. World J Urol 18:102–110PubMedGoogle Scholar
  130. Koivisto P, Kononen J, Palmberg C et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314–319PubMedGoogle Scholar
  131. Konishi N, Hiasa Y, Matsuda H et al. (1995) Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 147:1112–1122PubMedCentralPubMedGoogle Scholar
  132. Kornfeld S (1992) Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu Rev Biochem 61:307–330PubMedGoogle Scholar
  133. Korsmeyer SJ (1999) bcl-2 gene family and the regulation of programmed cell death. Cancer Res 59:1693s–1700sPubMedGoogle Scholar
  134. Krajewska M, Krajewski S, Epstein JI et al. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567–1576PubMedCentralPubMedGoogle Scholar
  135. Krajewski S, Tanaka S, Takayama S, Schibier MJ, Fenton W, Reed JC (1993) Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53:4701–4714PubMedGoogle Scholar
  136. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC (1994a) Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of bcl-2. Am J Pathol 145:1323–1336PubMedCentralPubMedGoogle Scholar
  137. Krajewski S, Krajewska M, Shabaik A et al. (1994b) Immunohistochemical analysis of in vivo patterns of bcl-X expression. Cancer Res 54:5501–5507PubMedGoogle Scholar
  138. Krajewski S, Blomqvist C, Franssila K et al. (1995a) Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471–4478PubMedGoogle Scholar
  139. Krajewski S, Bodrug S, Krajewska M et al. (1995b) Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 146:1309–1319PubMedCentralPubMedGoogle Scholar
  140. Kuczyk MA, Serth J, Bokemeyer C et al. (1998) The MXI1 tumor suppressor gene is not mutated in primary prostate cancer. Oncol Rep 5:213–216PubMedGoogle Scholar
  141. Kuiper GG, Ruiter PE de, Trapman J et al. (1993) Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. Biochem J 291:95–101PubMedCentralPubMedGoogle Scholar
  142. Kurimoto S, Moriyama N, Horie S et al. (1998) Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem J 30:27–32PubMedGoogle Scholar
  143. Labrie F, Dupont A, Belanger A et al. (1983) New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate 4:579–594PubMedGoogle Scholar
  144. Lang SH, Clarke NW, George NJ, Testa NG (1997) Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clin Exp Metastasis 15:218–227PubMedGoogle Scholar
  145. Langley E, Zhou ZX, Wilson EM (1995) Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270:29983–29990PubMedGoogle Scholar
  146. Lapointe J, Fournier A, Richard V, Labrie C (1999) Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 140:416–421PubMedGoogle Scholar
  147. Latham JP, Searle PF, Mautner V, James ND (2000) Prostatespecific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissuespecific adenovirus vector. Cancer Res 60:334–341PubMedGoogle Scholar
  148. Letterio JJ, Roberts AB (1998) Regulation of immune responses by IGF-beta. Annu Rev Immunol 16:137–161PubMedGoogle Scholar
  149. Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE (1997) Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 15:1115–1120PubMedGoogle Scholar
  150. Lilja H (1993) Significance of different molecular forms of serum PSA: the free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol Clin North Am 20:681–686PubMedGoogle Scholar
  151. Lim S, Lee HY, Lee H (1998) Inhibition of colonization and cell-matrix adhesion after nm23-H1 transfection of human prostate carcinoma cells. Cancer Lett 133:143–149PubMedGoogle Scholar
  152. Lou W, Krill D, Dhir R et al. (1999) Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 59:2329–2331PubMedGoogle Scholar
  153. Lu Y, Steiner MS (2000) Transcriptionally regulated adenovirus es for prostate-specific gene therapy. World J Urol 18:93–101PubMedGoogle Scholar
  154. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ (1999a) Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13:376–384PubMedGoogle Scholar
  155. Lu W, Luo Y, Kan M, McKeehan WL (1999b) Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate [published erratum appears in J Biol Chem 1999 274:28058]. J Biol Chem 274:12827–12834PubMedGoogle Scholar
  156. Lubaroff DM, Elzey B.D., Ratliff TL, Schlom J, Tartaglia J (1999) PSA-encoding adenovirus upduces potent antitumor immunity in a mouse prostate tumor model. J Urol 161:153Google Scholar
  157. Maffezzini M, Simonato A, Fortis C (1996) Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 28:282–286PubMedGoogle Scholar
  158. Mangelsdorf DJ, Thummel C, Beato M et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839PubMedGoogle Scholar
  159. Marcelli M, Ittmann M, Mariani S et al. (2000) Androgen receptor mutations in prostate cancer. Cancer Res 60:944–949PubMedGoogle Scholar
  160. Marengo SR, Sikes RA, Anezinis P et al. (1997) Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol Carcinog 19:165–175PubMedGoogle Scholar
  161. Mashimo T, Watabe M, Hirota S et al. (1998) The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 95:11307–11311PubMedCentralPubMedGoogle Scholar
  162. Matsubara A, Kan M, Feng S, McKeehan WL (1998) Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 58:1509–1514PubMedGoogle Scholar
  163. McDonnell TJ, Navone NM, Troncoso P et al. (1997) Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569–574PubMedGoogle Scholar
  164. McPhaul MJ, Marcelli M, Zoppi S, Wilson CM, Griffin JE, Wilson JD (1992) Mutations in the ligand-binding domain of the androgen receptor gene cluster in two regions of the gene. J Clin Invest 90:2097–2101PubMedCentralPubMedGoogle Scholar
  165. McPhaul MJ, Marcelli M, Zoppi S, Griffin JE, Wilson JD (1993) Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance. J Clin Endocrinol Metab 76:17–23PubMedGoogle Scholar
  166. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL (2000) Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.Prostate 43:88–100PubMedGoogle Scholar
  167. Miyake H, Hara I, Okamoto I et al. (1998) Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. J Urol 160:1562–1566PubMedGoogle Scholar
  168. Miyamoto H, Yeh S, Wilding G, Chang C (1998) Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95:7379–7384PubMedCentralPubMedGoogle Scholar
  169. Morita N, Uemura H, Tsumatani K et al. (1999) E-cadherin and alpha-, beta-and gamma-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer 79:1879–1883PubMedCentralPubMedGoogle Scholar
  170. Moul JW, Sesterhenn IA, Connelly RR et al. (1995) Prostatespecific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 274:1277–1281PubMedGoogle Scholar
  171. Moyret-Lalle C, Marcais C, Jacquemier J et al. (1995) ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 64:124–129PubMedGoogle Scholar
  172. Muir GH, Butta A, Shearer RJ et al. (1994) Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer 69: 130–134PubMedCentralPubMedGoogle Scholar
  173. Mulligan RC (1993) The basic science of gene therapy. Science 260:926–932PubMedGoogle Scholar
  174. Mydlo JH, Michaeli J, Heston WD, Fair WR (1988) Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate 13:241–247PubMedGoogle Scholar
  175. Myers RB, Grizzle WE (1996) Biomarker expression in prostatic intraepithelial neoplasia. Eur Urol 30:153–166PubMedGoogle Scholar
  176. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE (1994) Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86:1140–1145PubMedGoogle Scholar
  177. Nabel GJ, Nabel EG, Yang ZY et al. (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307–11311PubMedCentralPubMedGoogle Scholar
  178. Nakajima Y, DelliPizzi AM, Mallouh C, Ferreri NR (1996) TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines. Prostate 29:296–302PubMedGoogle Scholar
  179. Namba H, Iwadate Y, Tagawa M et al. (1996) Evaluation of the bystander effect in experimental brain tumors bearing herpes simplex virus-thymidine kinase gene by serial magnetic resonance imaging. Hum Gene Ther 7:1847–1852PubMedGoogle Scholar
  180. Nelson WG, Cho KR, Hsiang YH, Liu LF, Coffey DS (1987) Growth-related elevations of DNA topoisomerase II levels found in Dunning R3327 rat prostatic adenocarcinomas. Cancer Res 47:3246–3250PubMedGoogle Scholar
  181. Nelson JB, Hedican SP, George DJ et al. (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944–949PubMedGoogle Scholar
  182. Nelson JB, Chan-Tack K, Hedican SP et al. (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663–668PubMedGoogle Scholar
  183. Nishimura K, Kitamura M, Takada S et al. (1998) Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 5:276–281PubMedGoogle Scholar
  184. Noordzij MA, Steenbrugge GJ van, Schroder FH, van der Kwast TH (1999) Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 84:478–483PubMedGoogle Scholar
  185. Oka Y, Rozek LM, Czech MP (1985) Direct demonstration of rapid insulin-like growth factor II receptor internalization and recycling in rat adipocytes.Insulin stimulates 1251-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. J Biol Chem 260:9435–9442PubMedGoogle Scholar
  186. Olapade-Olaopa EO, Moscatello DK, MacKay EH et al. (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82:186–194PubMedCentralPubMedGoogle Scholar
  187. Pantuck AJ, Zisman A, Belldegrun AS (2000) Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions. World J Urol 18:143–147PubMedGoogle Scholar
  188. Papandreou CN, Usmani B, Geng Y et al. (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4:50–57PubMedGoogle Scholar
  189. Paradis V, Eschwege P, Loric S et al. (1998) De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin Pathol 51:798–802PubMedCentralPubMedGoogle Scholar
  190. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics. CA Cancer J Clin 46:5–27PubMedGoogle Scholar
  191. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J (1992) Cancer incidence in five continents, vol VI. International Agency for Research on Cancer, LyonGoogle Scholar
  192. Partin AW, Oesterling JE (1994) The clinical usefulness of prostate specific antigen: update 1994. J Urol 152:1358–1368PubMedGoogle Scholar
  193. Patel B, Naitoh J, Stiles A, Tso CL, Figlin R, Belldegrun A (1999) Effect of interleukin-2 gene therapy on prostate specific antigen in patients undergoing neoadjuvant and adjuvant gene therapy for prostate cancer. J Urol 161:337Google Scholar
  194. Paul R, Ewing CM, Jarrard DF, Isaacs WB (1997) The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol [Suppl 1] 79:37–43PubMedGoogle Scholar
  195. Pepper MS (1997) Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8:21–43Google Scholar
  196. Perez M, Regan T, Pflug B, Lynch J, Djakiew D (1997) Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 30:274–279PubMedGoogle Scholar
  197. Perinchery G, Bukurov N, Nakajima K, Chang J, Li LC, Dahiya R (1999) High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer. Int J Cancer 83:610–614PubMedGoogle Scholar
  198. Persad S, Attwell S, Gray V et al. (2000) Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase BlAkt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97:3207–3212PubMedCentralPubMedGoogle Scholar
  199. Pflug B, Djakiew D (1998) Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death. Mol Carcinog 23:106–114PubMedGoogle Scholar
  200. Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D (1995) Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 136:262–268PubMedGoogle Scholar
  201. Phillips SM, Barton CM, Lee SJ et al. (1994) Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70:1252–1257PubMedCentralPubMedGoogle Scholar
  202. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS (1991) The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145:199–202PubMedGoogle Scholar
  203. Potosky AL, Harlan LC, Stanford JL et al. (1999) Prostate cancer practice patterns and quality of life: the prostate cancer outcomes study. J Natl Cancer Inst 91:1719–1724PubMedGoogle Scholar
  204. Pratt WB (1993) The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem 268:21455–21458PubMedGoogle Scholar
  205. Prendergast NJ, Walther PJ (1995) Genetic alterations in prostate adenocarcinoma. Surg Oncol Clin N Am 4:241–255PubMedGoogle Scholar
  206. Prochownik EV, Eagle Grove L, Deubler D et al. (1998) Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer22:295–304PubMedGoogle Scholar
  207. Putz T, Culig Z, Eder IE et al. (1999) Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kin ase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59:227–233PubMedGoogle Scholar
  208. Qian J, Bostwick DG, Takahashi S et al. (1995) Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408–5414PubMedGoogle Scholar
  209. Qiu Y, Ravi L, Kung HJ (1998) Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393:83–85PubMedGoogle Scholar
  210. Raff MC (1992) Social controls on cell survival and cell death. Nature 356:397–400PubMedGoogle Scholar
  211. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438–4445PubMedGoogle Scholar
  212. Ragde H, Elgamal AA, Snow PB et al. (1998) Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83:989–1001PubMedGoogle Scholar
  213. Rajan R, Vanderslice R, Kapur S, Lynch J, Thompson R, Djakiew D (1996) Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 28:1–9PubMedGoogle Scholar
  214. Reed JC, Kitada S, Takayama S, Miyashita T (1994) Regulation of chemoresistance by the bcl-2 oncoprotein in nonHodgkin’s lymphoma and lymphocytic leukemia cell lines. Ann Oncol [Suppl1] 5:61–65PubMedGoogle Scholar
  215. Resnick MI (1987) Editorial comment on screening for prostate cancer. In: Ratliff TL, Catalona WJ (eds) Genitourinary cancer. Martinus Nijhoff, Boston, pp 94–99Google Scholar
  216. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M (1997) Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57:3189–3193PubMedGoogle Scholar
  217. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT (1994) Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 25:249–265PubMedGoogle Scholar
  218. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA (1997) The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 138:1145–1150PubMedGoogle Scholar
  219. Robertson CN, Roberson KM, Herzberg AJ, Kerns BJ, Dodge RK, Paulson DF (1994) Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues. Surg Oncol 3:237–242PubMedGoogle Scholar
  220. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57:2559–2563PubMedGoogle Scholar
  221. Sanda MG, Simons JW (1994) Gene therapy for urologic cancer. Urology 44:617–624PubMedGoogle Scholar
  222. Sanda MG, Smith DC, Charles LG et al. (1999) Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53:260–266PubMedGoogle Scholar
  223. Saric T, Brkanac Z, Troyer DA et al. (1999) Genetic pattern of prostate cancer progression. Int J Cancer 81:219–224PubMedGoogle Scholar
  224. Scher HI, Sarkis A, Reuter V. et al. (1995) Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545–550PubMedGoogle Scholar
  225. Schwartz S Jr, Caceres C, Morote J et al. (1999) Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis. Int J Oncol 14:367–371PubMedGoogle Scholar
  226. Shabaik AS, Krajewski S, Burgan A, Krajewska M, Reed JC (1994) bcl-2 proto-oncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol 3:17-27Google Scholar
  227. Shalev M, Miles BJ, Thompson TC et al. (2000) Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. World J Urol 18:125–129PubMedGoogle Scholar
  228. Shi XB, Gumerlock PH, deVere White RW (1996) Molecular biology of prostate cancer. World J Urol 14:318–328PubMedGoogle Scholar
  229. Simons JW, Mikhak B, Chang JF et al. (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160–5168PubMedGoogle Scholar
  230. Sordello S, Bertrand N, Plouet J (1998) Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 251:287–290PubMedGoogle Scholar
  231. Soussi T, May P (1996) Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol 260:623–637PubMedGoogle Scholar
  232. Steiner MS (1995) Transforming growth factor-beta and prostate cancer. World J Urol 13:329–336PubMedGoogle Scholar
  233. Steiner MS, Anthony CT, Lu Y, Holt JT (1998) Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 9:747–755PubMedGoogle Scholar
  234. Steiner MS, Zhang Y, Farooq F, Lerner J, Wang Y, Lu Y (2000) Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther 7:360–372PubMedGoogle Scholar
  235. Story MT, Hopp KA, Molter M, Meier DA (1994) Characteristics of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates. Growth Factors 10:269–280PubMedGoogle Scholar
  236. Story MT, Hopp KA, Molter M (1996) Expression of transforming growth factor beta 1 (TGF beta 1),-beta 2, and-beta 3 by cultured human prostate cells. J Cell Physiol 169:97–107PubMedGoogle Scholar
  237. Sweeney P, Pisters LL (2000) Ad5CMVp53 gene therapy for locally advanced prostate cancer-where do we stand? World J Urol 18:121–124PubMedGoogle Scholar
  238. Tamboli P, Amin MB, Xu HJ, Linden MD (1998) Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatie adenocarcinoma and benign prostate. Mod Pathol 11:247–252PubMedGoogle Scholar
  239. Tanaka A, Furuya A, Yamasaki M et al. (1998) High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutrallzmg monoclonal antibody against FGF 8. Cancer Res 58:2053–2056PubMedGoogle Scholar
  240. Taplin ME, Bubley GJ, Shuster TD et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398PubMedGoogle Scholar
  241. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr (1997) p53:bcl-2 and retinoblastoma proteins as longterm prognostic markers in localized carcinoma of the prostate. J Urol 158:131–137PubMedGoogle Scholar
  242. Thomas T.Z., Chapman SM, Hong W. et al. (1998) Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia. Prostate 34:34–43PubMedGoogle Scholar
  243. Thompson IM, Zeidman EJ (1991) Presentation and clinical course of patients ultimately succumbing to carcinoma of the prostate. Scand J Urol Nephrol 25: 111–114PubMedGoogle Scholar
  244. Trapman J, Cleutjens KB (1997) Androgen-regulated gene expression in prostate cancer. Semin Cancer Biol 8:29–36PubMedGoogle Scholar
  245. Tricoli JV, Gumerlock PH, Yao JL et al. (1996) Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer 15:108–114PubMedGoogle Scholar
  246. Trikha M, Raso E, Cai Y et al. (1998) Role of alphaII(b)beta3 integrin in prostate cancer metastasis. Prostate 35:185–192PubMedGoogle Scholar
  247. Truong LD, Kadmon D, McCune BK, Flanders K.C., Scardino PT, Thompson TC (1993) Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24:4–9PubMedGoogle Scholar
  248. Tsai MJ, O’Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members.Annu Rev Biochem 63:451–486PubMedGoogle Scholar
  249. Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214–5218PubMedCentralPubMedGoogle Scholar
  250. Ueda T, Komiya A, Emi M et al. (1997) Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer. Genes Chromosomes Cancer 20:140–147PubMedGoogle Scholar
  251. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E (1992) Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31:2393–2399PubMedGoogle Scholar
  252. Verma RS, Manikal M, Conte RA, Godec CJ (1999) Chromosomal basis of adenocarcinoma of the prostate. Cancer Invest 17:441–447PubMedGoogle Scholar
  253. Vieweg J, Rosenthai FM, Bannerji R et al. (1994) Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760–1765PubMedGoogle Scholar
  254. Visakorpi T, Kallioniemi AH, Syvanen AC et al. (1995) Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342–347PubMedGoogle Scholar
  255. Wajsman Z, Chu TM (1987) Detection and diagnosis of prostatic cancer. In: Murphy GP (ed) Prostatic cancer. PSG, Littleton, MA, pp 94–99Google Scholar
  256. Walsh PC, Lepor H, Eggleston JC (1983) Radical prostatectomy with preservation of sexual function: anatomical and pathological consideration. Prostate 4:473–485PubMedGoogle Scholar
  257. Wang Q.F., Tilly KI, Tilly JL et al. (1996) Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP.Endocrinology 137:5476–5483PubMedGoogle Scholar
  258. Wang SI, Parsons R, Ittmann M (1998) Homozygous deletion of the PTEN tumor suppressor gene in a sub set of prostate adenocarcinomas. Clin Cancer Res 4:811–815PubMedGoogle Scholar
  259. Ware JL (1993) Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 12:287–301PubMedGoogle Scholar
  260. Waterhouse RL, Resnick MI (1989) The use of transrectal prostatic ultrasonography in the evaluation of patients with prostatic carcinoma. J Urol 141:233–239PubMedGoogle Scholar
  261. Weigel NL, Zhang Y. (1998) Ligand-independent activation of steroid hormone receptors. J Mol Med 76:469–479PubMedGoogle Scholar
  262. Wikstrom P, Bergh A, Damber JE (2000) Transforming growth factor-betal and prostate cancer. Scand J Urol Nephrol 34:85–94PubMedGoogle Scholar
  263. Willman JH, Holden JA (2000) Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate. Prostate 42:280–286PubMedGoogle Scholar
  264. Wiman KG (1993) The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB J 7:841–845PubMedGoogle Scholar
  265. Wolk A, Mantzoros CS, Andersson SO et al. (1998) Insulinlike growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90:911–915PubMedGoogle Scholar
  266. Xie H, Turner T, Wang MH, Singh RK, Siegal GP, Wells A (1995) In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 13:407–419PubMedGoogle Scholar
  267. Yin XM, Oltvai ZN, Korsmeyer SJ (1994) BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369:321–323PubMedGoogle Scholar
  268. Yoshida BA, Chekmareva MA, Wharam JF et al. (1998) Prostate cancer metastasis-suppressor genes: a current perspective.In Vivo 12:49–58PubMedGoogle Scholar
  269. Zelefsky MJ, Cowe D, Fuks Z et al. (1999) Long term tolerance of high-dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85:2460–2468PubMedGoogle Scholar
  270. Zhang XH, Sakamoto H, Takenaka I (1996) Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Br J Urol 77:441–444PubMedGoogle Scholar
  271. Zhang M, Magit D, Sager R (1997) Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci USA 94:5673–5678PubMedCentralPubMedGoogle Scholar
  272. Zhu N, Liggitt D, Liu Y, Debs R (1993) Systemic gene expression after intravenous DNA delivery into adult mice. Science 261:209–211PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Ursula Elsässer-Beile
  • Wolfgang Schultze-Seemann
  • Ulrich Wetterauer

There are no affiliations available

Personalised recommendations